Document is current

Any future updates will be listed below

Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors

Crossref DOI link: https://doi.org/10.1136/bmjdrc-2019-000725

Published Online: 2019-10-04

Published Print: 2019-10

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark